Home » Roche’s Tarceva Extends Time to Disease Progession in Lung Cancer Study
Roche’s Tarceva Extends Time to Disease Progession in Lung Cancer Study
Roche Holding AG’s Tarceva medicine extended the time patients with a certain kind of newly diagnosed lung cancer lived without their disease getting worse in a late-stage study.
Bloomberg
Bloomberg
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May